SEC Form 4 · accession 0001562180-18-004913
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Jonas
Officer — President & CEO · Director
Period of report
Dec 7, 2018
Accepted (ET)
Dec 11, 2018 · 5:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $47.70 | Dec 7, 2018 | A | 23,100 | A | — | Feb 6, 2027 | Common Stock | 23,100 | 23,100 | D |
Explanation of responses
- F1On February 6, 2017, the reporting person was granted an option to purchase 70,000 shares of common stock. The option vests upon the achievement of certain milestones, one of which was met on December 7, 2018, resulting in the vesting of the option as to 23,100 shares.